What is Euroapi?
Euroapi operates as a specialized entity dedicated to the development, manufacturing, and supply of active pharmaceutical ingredients (APIs) for both human and veterinary medicine. The company functions as a vital partner for pharmaceutical and biotechnology organizations, providing a comprehensive suite of services that includes contract development and manufacturing. Through its sophisticated production technologies, Euroapi addresses the growing demand for supply chain reliability and quality assurance in the healthcare sector. Its market position is defined by a commitment to sustainability and innovation, ensuring that it remains a cornerstone for drug development and commercial-scale manufacturing in an increasingly complex global regulatory environment.
How much funding has Euroapi raised?
Euroapi has raised a total of $474M across 1 funding round:
Debt
$474M
Debt (2024): $474M with participation from Sanofi
Key Investors in Euroapi
Sanofi
Sanofi is a global biopharmaceutical leader focused on scientific innovation, developing medicines and vaccines across immunology, rare diseases, and oncology to improve patient outcomes worldwide.
What's next for Euroapi?
With the recent influx of capital, Euroapi is strategically positioned to optimize its manufacturing footprint and enhance its technological infrastructure. The company is expected to prioritize the scaling of its contract development and manufacturing services, allowing it to meet the evolving needs of its global client base. By focusing on supply chain resilience and the integration of advanced production methodologies, Euroapi aims to strengthen its competitive advantage. Future growth will likely be driven by a continued emphasis on high-quality API production and the expansion of its service portfolio, ensuring the firm remains a preferred partner for organizations navigating the challenges of modern pharmaceutical development and commercialization.
See full Euroapi company page
